Explore this article's sources with AI
Follow PeptideMethods on Google
Foundayo and sleep apnea trial results
Two phase 3 trials found that oral orforglipron reduced sleep-apnea events, but the result is not a new FDA indication.
Why we wrote this. The headline invites a direct comparison with Zepbound. We separated the two trial programs and checked the claim against the paper, registry and FDA label.
In this article (5 sections)
Foundayo, Eli Lilly's brand of oral orforglipron, reduced breathing interruptions over 52 weeks in two phase 3 trials of adults with moderate to severe obstructive sleep apnea and obesity or overweight. The results are encouraging, but they do not show that the pill treats sleep apnea independently of weight loss, and Foundayo is not FDA-approved for sleep apnea.[1][2][3]
Orforglipron is a once-daily, nonpeptide GLP-1 receptor agonist. That makes it different from injectable peptide drugs such as tirzepatide, sold as Zepbound in the United States. Foundayo's current US label covers chronic weight management in adults with obesity, or overweight plus at least one weight-related condition. Sleep apnea is not listed as an approved indication.[4]
What the ATTAIN-OSA trials found
ATTAIN-OSA enrolled 712 adults without diabetes. All had a body mass index of at least 27 and moderate to severe obstructive sleep apnea. The master protocol contained two randomized, double-blind, placebo-controlled trials. Trial 1 included 363 people who were not using positive airway pressure (PAP) therapy. Trial 2 included 349 people who were using PAP. Participants received once-daily orforglipron or placebo for 52 weeks.[2][3]
The primary outcome was change in the apnea-hypopnea index (AHI), the number of apneas and hypopneas recorded per hour of sleep. In trial 1, mean AHI fell by 17.8 events per hour with orforglipron and by 4.5 with placebo. The estimated difference was 13.2 fewer events per hour. In trial 2, mean AHI fell by 17.3 events per hour with orforglipron and by 5.3 with placebo, an estimated difference of 12.0 events per hour. Both comparisons met the trial's threshold for statistical significance.[2]
Six of seven multiplicity-controlled secondary outcomes also favored orforglipron. STAT reported that, in trial 1, 28% of treated participants reached remission or mild disease compared with 13% on placebo. That result is useful context, but it also shows that most participants did not reach that threshold after one year.[1][2]
The comparison with Zepbound needs care
The Foundayo and Zepbound sleep-apnea programs were separate trials, not a head-to-head comparison. Cross-trial differences in participants, baseline measurements, treatment and analysis can distort a simple comparison of headline numbers. The oral results therefore cannot establish that one drug is better than the other.[2][5]
The earlier SURMOUNT-OSA trials did report larger average AHI reductions with injectable tirzepatide. Among adults with obesity and moderate to severe obstructive sleep apnea, mean AHI fell by 25.3 events per hour with tirzepatide versus 5.3 with placebo in the trial without PAP. In the trial with PAP, the reductions were 29.3 and 5.5 events per hour. Those figures explain the caution in STAT's coverage, but they remain an indirect comparison.[5]
Zepbound has a US indication for moderate to severe obstructive sleep apnea in adults with obesity. Foundayo does not. Readers can see the broader evidence and current status on our tirzepatide regulation overview. A positive trial result and an FDA-approved indication are separate facts.[4][5]
Safety findings were mainly gastrointestinal
Gastrointestinal events were the most commonly reported adverse events in ATTAIN-OSA. They occurred in 68.0% of participants assigned to orforglipron and 37.4% assigned to placebo in trial 1. In trial 2, the corresponding rates were 70.6% and 36.6%. The published abstract does not turn those totals into a personal risk estimate, and people considering treatment need the complete safety profile rather than a single event category.[2]
The FDA label lists nausea, constipation, diarrhea and vomiting among Foundayo's common adverse reactions. It also carries warnings concerning pancreatitis, severe gastrointestinal reactions, kidney injury due to volume depletion, gallbladder disease and other risks. The label states that Foundayo is a prescription medicine and should not be used with another GLP-1 receptor agonist.[4]
What we don't yet know
ATTAIN-OSA lasted 52 weeks, so it cannot answer whether the AHI improvement persists for several years or what happens after treatment stops. The trials enrolled adults with overweight or obesity and excluded people with type 1 or type 2 diabetes, central or mixed sleep apnea meeting the protocol threshold, and several other conditions. The findings should not be extended to groups the trial did not study.[2][3]
The trial also does not settle how much of the sleep-apnea change came from weight loss and whether orforglipron has additional effects on sleep-disordered breathing. Nor does it replace established sleep-apnea care. PAP use defined the two trial groups, and the study was designed to measure an added drug effect against placebo, not to tell an individual reader whether to start, stop or change PAP therapy.[2][3]
What the result means now
The trials provide peer-reviewed evidence that oral orforglipron can reduce AHI in the population studied. They do not create a sleep-apnea indication, prove superiority or equivalence to tirzepatide, or support self-directed treatment. Anyone with suspected or diagnosed sleep apnea should discuss the findings with a qualified healthcare professional who can consider sleep testing, current treatment and the drug's full safety information.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
Is Foundayo approved for sleep apnea?
No. Foundayo is FDA-approved for chronic weight management in certain adults. Its current US label does not list obstructive sleep apnea as an approved indication.
What is orforglipron?
Orforglipron is a once-daily oral, nonpeptide GLP-1 receptor agonist. Eli Lilly markets it in the United States under the brand Foundayo.
Did Foundayo work better than Zepbound for sleep apnea?
The trials did not test Foundayo against Zepbound. Results from separate programs can provide context, but they cannot prove that one drug works better than the other.
Can Foundayo replace PAP therapy?
The trials do not support that conclusion. One trial studied people not using PAP and the other studied people using PAP. Treatment decisions should be made with a qualified healthcare professional.
Sources
- [1]STAT News: Eli Lilly's GLP-1 pill Foundayo helped alleviate sleep apnea in studiesTier 2 · expert↩
- [2]JAMA: Orforglipron for Obstructive Sleep Apnea, ATTAIN-OSA (PMID 43002161)Tier 1 · primary↩
- [3]ClinicalTrials.gov: ATTAIN-OSA master protocol (NCT06649045)Tier 1 · primary↩
- [4]FDA prescribing information for Foundayo (orforglipron), revised April 2026Tier 1 · primary↩
- [5]New England Journal of Medicine: Tirzepatide for Obstructive Sleep Apnea and Obesity (PMID 38912654)Tier 1 · primary↩
No revisions yet. First published .